ClinicalTrials.gg
RecruitingNCT07216846GREAT PHARMUpdated Jan 8, 2026

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

An interventional study of DNA care pathway in Fall, Fall Accident and Poly Pharmacy, sponsored by Florida Atlantic University. Recruiting at 1 site in United States. Open to participants aged 65 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Florida Atlantic University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
65 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States — 13 open to participants now, 18 under way, 2 of them phase 3. Drug-Related Side Effects and Adverse Reactions · United States.

Planned enrollment
9th of 95
1,000 · median 96
Started
2026
with 4 others
No phase
38 of 140
4 open now
Primary completion
2027-12
later than 9 of 17 live
Registered
137th of 140
by date

Among the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, this one is the 9th largest by planned enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2026, is one of 38 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 137th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

13 of the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 65 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, or all of them as a file.
02

Study summary

The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications.

The main questions it aims to answer are:

  • Can DNA-based prescribing reduce medication-related side effects, especially falls and fall-related injuries?
  • Does providing pharmacogenomic results to primary care physicians improve medication safety compared with usual care?

Researchers will compare two groups:

  1. DNA Care Pathway: Physicians receive patients' DNA results to guide prescribing.
  2. Emergency Department Care Pathway: Physicians provide usual care; DNA results are shared only after study completion.

Participants will:

  • Provide a cheek swab sample for DNA analysis (1 minute).
  • Receive monthly follow-up phone calls for 6 months to track falls, injuries, medication changes, and side effects.
  • Complete a fall and medication calendar.
  • Allow researchers to review primary care physician medical records for study outcomes.

Approximately 1,000 participants will take part, with follow-up lasting about 6-7 months.

Read the detailed description

Background and Rationale Medication prescribing is one of the most common medical interventions. In the U.S., 81% of adults report taking at least one medication in the past week, and 50% take prescription medications. Among older adults, 39% meet the criteria for polypharmacy, defined as the use of five or more chronic medications.

Polypharmacy is strongly associated with adverse drug events (ADEs). Each day, approximately 750 older adults in the U.S. are hospitalized due to ADEs, with half of these patients taking five or more medications. Nearly 60% of older adults are prescribed at least one potentially unnecessary medication.

Traditional prescribing often follows a "one-size-fits-all" approach, which does not account for genetic differences in how individuals metabolize drugs. These genetic variations can lead to ineffective treatment or harmful side effects. Pharmacogenomic-guided prescribing may provide a safer, more personalized approach by identifying drug-gene interactions and tailoring medication choices.

Falls and Medication Safety Falls are one of the most serious and preventable ADEs among older adults. Falls are the leading cause of injury-related morbidity and mortality in older populations, with over 700,000 hospital falls in the U.S. annually. Polypharmacy, especially the use of fall-risk-increasing drugs (FRIDs), contributes substantially to this problem.

By integrating pharmacogenomic testing into medication management, clinicians may be able to reduce fall-related ADEs and improve overall prescribing safety.

Study Objectives and Aims The Geriatric Emergency Department Pharmacologic Harm Prevention Project (The GREAT PHARM) seeks to evaluate whether pharmacogenomic-guided prescribing can reduce ADEs and falls among older adults.

Aim 1: Compare the incidence of recurrent falls, ADE-related emergency department (ED) visits, and all-cause mortality in patients receiving pharmacogenomic-guided medication optimization versus usual care.

Secondary Aim 1: Assess barriers to implementing pharmacogenomic-based prescribing. Aim 2: Determine the prevalence of harmful gene-drug interactions and abnormal drug levels in older adults presenting to the ED after a fall.

Aim 3: Compare self-reported wellbeing and health satisfaction between patients who receive pharmacogenomic-guided prescribing and those receiving usual care.

Study Design

  • This is a randomized clinical trial enrolling approximately 1,000 participants aged 65 and older.
  • Eligibility: Adults ≥65 years presenting to the ED with a ground-level fall.
  • Exclusion criteria: Hospice care or Do Not Resuscitate (DNR) status.

Randomization: Participants will be randomized (via REDCap) into two study arms:

  1. Control Group (Current Care) - Standard prescribing practices; pharmacogenomic results provided to primary care physicians only after study completion.
  2. Intervention Group (Pharmacogenomic-Guided Prescribing) - Standard care plus pharmacogenomic results provided to the primary care physician during the study for medication optimization.

Interventions

All participants will:

  • Provide a one-time cheek swab sample for DNA analysis (testing 26 metabolic enzyme systems).
  • If blood is drawn for routine ED care, provide an additional small blood sample (\~5cc) for drug-level analysis. Blood concentrations will be assessed using mass spectrometry at the Florida Atlantic University Bioanalytical Core Facility.
  • Complete a monthly calendar to record medication changes, falls, and fall-related injuries.
  • Participate in monthly follow-up phone calls (for 6-7 months) to track falls, side effects, and overall health.
  • Authorize access to primary care physician medical records for up to one year to confirm study outcomes.

Outcome Measures

Primary Outcomes:

  1. Incidence of recurrent falls during 6-7 months of follow-up.
  2. Incidence of ADE-related ED visits.
  3. All-cause mortality.

Secondary Outcomes:

  1. Prevalence of harmful gene-drug interactions in older adults presenting with falls.
  2. Prevalence of abnormal drug levels in patients with pharmacogenomic variations.
  3. Patient-reported wellbeing and health satisfaction.
  4. Barriers to implementation of pharmacogenomic-guided prescribing.

Duration of Participation Each participant will be followed for approximately 6-7 months, with ongoing monitoring through phone calls, calendars, and medical record review.

Significance This trial will evaluate whether personalized prescribing guided by DNA testing can reduce medication-related harm, prevent recurrent falls, and improve overall quality of life for older adults. If successful, the study will provide strong evidence for integrating pharmacogenomic-guided prescribing into standard clinical care for geriatric patients at risk of medication-related harm.

03

Conditions studied

  • Fall
  • Fall Accident
  • Poly Pharmacy
  • Adverse Drug Events
  • Pharmacogenomic Drug Interaction
  • Pharmacogenomic Testing

Keywords

  • Fall
  • Geriatric
  • Pharmacogenomic
  • adverse drug event
04

Who can participate

Ages eligible
65 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over the age of 65 with a ground level fall

Exclusion criteria

Exclusion Criteria:

  • hospice and/or DNR status.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Pharmacogenomic-Guided Prescribing pathway

    Pharmacogenomic test results will be transmitted to the participant's primary care physician to support medication optimization and prescribing decisions. Follow-up assessments will be conducted by telephone approximately 14 days after enrollment and then monthly for six months. These structured interviews will capture information on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions. Participants will also complete a monthly calendar to document medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed for corroborating information on falls, fall-related injuries, medication changes, medication-related side effects, and newly diagnosed medical problems.

    Other: DNA care pathway

  • No intervention
    Emergency Department care pathway ---control

    Participants randomized to the current Emergency Department care pathway will continue to receive standard prescribing practices without immediate use of pharmacogenomic results. Follow-up assessments will occur by telephone approximately 14 days after enrollment and then monthly for six months. These calls will collect data on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions. Participants will also complete a monthly calendar documenting medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed to identify additional falls, injuries, medication changes, side effects, and new medical problems. At the conclusion of the study, pharmacogenomic testing results will be provided to the participant's primary care physician to support future prescribing decisions.

Interventions

  • OtherDNA care pathway

    Pharmacogenomic test results will be transmitted to the participant's primary care physician to support medication optimization and prescribing decisions. Follow-up assessments will be conducted by telephone approximately 14 days after enrollment and then monthly for six months. These structured interviews will capture information on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions. Participants will also complete a monthly calendar to document medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed for corroborating information on falls, fall-related injuries, medication changes, medication-related side effects, and newly diagnosed medical problems.

06

What researchers measure

Primary outcomes

  1. Recurrent falls -self reported and chart review

    Incidence of recurrent falls during 6-7 months of follow-up. Around the fourteenth day of the study and then once a month for the following six months, participants will receive a follow-up phone call to assess any falls that may have occurred. In addition, each participant will receive a calendar to record falls during the month. At six-month, the primary care physician medical records will be reviewed to check for any additional falls.

    Time frame: 6-7 months

  2. Incidence of ADE-related ED visits- self reported and chart review

    Incidence of ADE-related ED visits during 6-7 months of follow-up. Around the fourteenth day of the study and then once a month for the following six months, participants will receive a follow-up phone call to assess any ADE-related ED visits that may have occurred. At six-month, the primary care physician medical records will be reviewed to check for any additional ADE-related ED visits.

    Time frame: Time Frame: 6-7 months

  3. All-cause mortality - Florida Death Registry

    During 6-7 months of follow-up. All participants will be cross-referenced with the Florida Death Registry to identify mortality outcomes

    Time frame: Time Frame: 6-7 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No current plan to do it

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 71 non-industry interventional studies with no phase under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 23 months is below that.

Counting every sponsor, half of 73 studies reached it within 26 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 15, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216846
Lead sponsor
Florida Atlantic University
Responsible party
Richard Shih (Principal Investigator, MD, Florida Atlantic University) — Principal investigator
First posted
Oct 15, 2025
Start date
Jan 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Richard Shih, Professor, MD
Contact
rshih@health.fau.edu
561-737-7733 ext. 87410
Scott Alter, Professor, MD
Contact
alters@health.fau.edu
561-737-7733 ext. 87410
Richard Shih, MD
principal investigator · Florida Atlantic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion